|
Kevin Hrusovsky was appointed President and CEO of Caliper Life Sciences immediately following the acquisition of Zymark Corporation by Caliper in July 2003. Prior to the acquisition Mr. Hrusovsky served as President and CEO for Zymark starting in late 1996. Mr. Hrusovsky successfully transformed Zymark from a custom robotics company into a formidable Life Sciences "Tools" company through acquisitions R&D investment and recruitment of top industry talent. Under Mr. Hrusovsky's leadership Zymark developed a strong global channel into the biotechnology and pharmaceutical industry with subsequent expansion into the genomics and proteomics market. Mr. Hrusovsky has senior management relationships throughout the pharmaceutical and biotechnology industries and has been instrumental in developing strategic collaborations with Johnson & Johnson Pfizer Boehringer-Ingelheim Amgen Millennium Aventis Glaxo Molecular Devices Affymetrix Qiagen Dako and Eppendorf.
Before joining Zymark Mr. Hrusovsky was president of the Pharmaceutical Division at FMC and ran the Teflon and other specialty businesses at Dupont. His entire career has been associated with managing transformative innovation into sustainable profitable enterprises. He is on the Board of Directors of Xenogen Corporation the Global Research Council for Children’s Hospital Boston and is a member of the Association of Laboratory Automation Steering Committee. He received an Honorary Doctorate degree from Framingham State University for contributions to life sciences. Mr. Hrusovsky holds a BSME from Ohio State and M.B.A. from Ohio University. He and his family are authentic Buckeyes! | 